Avoro Capital Advisors LLC
Q2 2023 13F-HR Holdings
Net value change ($000)
+626,023
(9.3%)
New positions
6
Sold out positions
1
Turnover %
2.5%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| APLS | 279,333 | 38.1% |
| KRYS | 160,534 | 114.6% |
| IVERIC bio, Inc. | 151,243 | 91.4% |
| MLTX | 87,975 | NEW |
| ROIV | 58,526 | NEW |
| FOLD | 41,387 | 13.7% |
| SRPT | 26,906 | 5.3% |
| CymaBay Therapeutics, Inc. | 22,969 | 25.6% |
| NUVL | 18,191 | 36.9% |
| XENE | 13,279 | 7.6% |
Top Reduces (Value $000, Stocks/ETFs)
| MDGL | -53,767 | -13.3% |
| Horizon Therapeutics Public Ltd Co | -44,030 | -5.8% |
| ASND | -36,942 | -10.4% |
| BMRN | -36,892 | -9.6% |
| Seagen Inc. | -26,178 | -7.2% |
| KYMR | -25,598 | -22.4% |
| AMLX | -13,881 | -100.0% |
| ALNY | -11,470 | -5.2% |
| DICE Therapeutics, Inc. | -10,987 | -9.7% |
| RNAM | -10,693 | -27.8% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|